CA
CANF.US Can Fite Biopharma Ltd ADR
- Market cap
- USD 4.30M
- P/E
- -
- P/B
- 0.93x
- ROE
- -189.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CANF.US undervalued?
Graham numberThe Graham number of Can Fite Biopharma Ltd ADR cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Can Fite Biopharma Ltd ADR fundamental analysis
No fundamental analysis for Can Fite Biopharma Ltd ADR yet.
Can Fite Biopharma Ltd ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Can Fite Biopharma Ltd ADR
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the trea…
Full company profileCan Fite Biopharma Ltd ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Can Fite Biopharma Ltd ADR annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 170K | 845K | 3.82M | 2.03M | 763K | 853K | 810K | 743K | 674K | 408K | 404K |
| Gross Profit | 170K | 845K | 3.82M | 2.03M | 763K | 853K | 810K | 743K | 674K | 384K | 404K |
| Operating Income | -8.63M | -7.38M | -5.41M | -12.0M | -14.1M | -12.8M | -10.1M | -8.20M | -8.13M | -10.0M | -9.36M |
| EBITDA | -8.68M | -7.17M | -6.13M | -12.0M | -14.1M | -12.8M | -10.1M | -8.18M | -8.12M | -10.0M | -9.36M |
| Net Income | -6.90M | -4.97M | -6.57M | -12.6M | -14.4M | -12.6M | -10.2M | -7.63M | -7.88M | -9.91M | -9.20M |
| EPS | -0.50 | -0.15 | -0.34 | -0.29 | -0.08 | -0.05 | -0.03 | -0.01 | -0.01 | -0.08 | -2.48 |
| Balance Sheet | |||||||||||
| Total Assets | 10.2M | 7.83M | 7.95M | 8.17M | 9.52M | 20.3M | 9.28M | 9.99M | 9.12M | 9.51M | 8.06M |
| Total Liabilities | 6.29M | 4.78M | 4.94M | 5.73M | 3.45M | 5.87M | 4.81M | 3.75M | 3.68M | 3.92M | 3.20M |
| Shareholders' Equity | 3.87M | 3.05M | 3.02M | 2.44M | 6.07M | 14.4M | 4.47M | 6.24M | 5.44M | 5.59M | 4.86M |
| Cash & Short-term Investments | 8.11M | 3.50M | 3.89M | 2.76M | 8.34M | 19.1M | 7.98M | 8.92M | 7.89M | 8.54M | 7.04M |
| Total Debt | - | - | - | 75.0K | 67.0K | 124K | 62.0K | 40.0K | 104K | 71.0K | 49.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.93M | -9.52M | -4.16M | -10.8M | -12.1M | -9.86M | -10.8M | -8.44M | -7.64M | -9.02M | -10.6M |
| Capital Expenditure | 10.4K | 6.91K | 33.0K | 3.00K | 26.0K | 11.0K | 9.00K | 2.00K | 5.00K | 2.02K | 2.00K |
| Free Cash Flow | -8.94M | -9.53M | -4.19M | -10.8M | -12.1M | -9.87M | -10.8M | -8.44M | -7.64M | -9.02M | -10.6M |
| Ratios | |||||||||||
| ROE | -178.4% | -162.7% | -217.9% | -517.0% | -237.8% | -87.6% | -228.9% | -122.3% | -145.0% | -177.1% | -189.5% |
| ROA | -67.8% | -63.4% | -82.6% | -154.5% | -151.7% | -62.2% | -110.3% | -76.4% | -86.4% | -104.1% | -114.2% |
| Net Profit Margin | -4,069.3% | -588.2% | -172.0% | -621.3% | -1,892.9% | -1,476.6% | -1,263.7% | -1,027.5% | -1,169.1% | -2,426.7% | -2,277.7% |
| Debt to Equity | - | - | - | 0.03x | 0.01x | 0.01x | 0.01x | 0.01x | 0.02x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Can Fite Biopharma Ltd ADR dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 2.59M | 0.01 | - |
| 2021 | USD 715K | 0.00 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Jan 5, 2026.
Who owns Can Fite Biopharma Ltd ADR
- Insiders 0.00%
- Institutions 2.47%
- Public & others 97.53%
- Shares outstanding 3.03M
- Free float 2.14M
Can Fite Biopharma Ltd ADR company profile
- Company name
- Can Fite Biopharma Ltd ADR
- Ticker
- CANF.US
- Exchange
- USA Stocks
- Listed since
- Nov 6, 2012
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- 26 Ben Gurion Street, Ramat Gan, Israel, 5257346
- Phone
- 972 3 924 1114
- Website
- canfite.com
About Can Fite Biopharma Ltd ADR
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Can Fite Biopharma Ltd ADR management
4- Dr. Pnina Fishman Ph.D.Founder, Chief Scientific Officer & Executive Chairperson · born 1948
- Mr. Motti FarbsteinCEO, CFO, Financial & Operating Officer · born 1964
- Dr. Sari Fishman Ph.D.Vice President of Business Development · born 1972
- Dr. Stephen A. Harrison FACP, M.D.Member of Clinical Advisory Board & Consulting Chief Medical Officer